Accueil > Actualité
Actualite financiere : Actualite bourse

Merck: encouraging new results for Keytruda

(CercleFinance.com) - Merck announced yesterday that a Phase 3 trial of Keytruda met one of its two primary endpoints of disease-free survival (DFS) as adjuvant therapy for patients with certain non-small cell lung cancers (NSCLC).


As a result, adjuvant treatment with Keytruda resulted in a statistically significant and clinically meaningful improvement in DFS compared to placebo in the general population of patients with stage IB-IIIA NSCLC.

The company said that Keytruda has become fundamental to the treatment of metastatic non-small cell lung cancer and we continue to advance research to explore its potential to help fight cancer earlier.


Copyright (c) 2022 CercleFinance.com. All rights reserved.
 

societes

marches

tendances

 
Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.